

Recalculation of terms for warrants of series TO 4

At an extraordinary general meeting in Prostatype Genomics AB (publ) ("Prostatype" or "the Company") on October 22, 2024, it was decided to implement a consolidation – a reverse split - of shares 1:1,000, meaning that one thousand (1,000) shares were combined into one (1) new share. As previously communicated, the record date for the combination of shares was 1 November 2024, which means that the share price reflects the effect of the combination of shares from this date. The new ISIN code for the Company's share ("PROGEN") is hereafter SE0023261532.

Recalculation of warrant of series TO 4

Due to the consolidation of shares, a recalculation takes place in accordance with the terms of the Company's warrants of series TO 4 regarding the subscription price and number of shares that each warrant gives the right to subscribe for, with the aim of neutralizing the effect of the consolidation of shares. Other terms for the warrants of series TO 4 remain unchanged, such as the time for exercising the warrants, etc. The total number of outstanding warrants does not change, nor does the ISIN code for warrant TO 4 (SE0022574554).

The new subscription price per share for warrants of series TO 4 shall, as before, correspond to 70 percent of the volume-weighted average price for the Company's share on the Nasdaq First North Growth Market during the period from and including November 11, 2024 to and including November 22, 2024, however not lower than the share's quota value (which is 0.10 SEK after consolidation of shares and reduction of the share capital), and the new number of shares that each one (1) warrant entitles to subscription for amounts to 0.001 shares after the recalculation (previously 1 share). It is not possible to subscribe for part of a share, which means that one thousand (1,000) warrants of series TO 4 are required to subscribe for one (1) new share in the Company. The subscription price must be rounded to the nearest whole öre.

Subscription of shares with the support of warrants of series TO 4 can take place during the period from and including November 25, 2024 to and including December 9, 2024 and the subscription price will be announced the day before the first day of the subscription period.

Please also refer to the FAQ on the reverse split available on the Prostatype website.

<https://prostatype.se/app/uploads/sites/7/2024/02/prostatype-genomics-ab-faq-reverse-split-shares-warrants-etc-2024a.pdf>

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

Certified Advisor

Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se

About Prostatype Genomics AB

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.